ArticleAmerican journal of translational research2026
Dihydroquercetin alleviates mitochondrial dysfunction and inhibits NLRP3-mediated pyroptosis in primary hepatocytes from chronic liver failure patients.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the protective effects of dihydroquercetin (DHQ) on mitochondrial function in primary hepatocytes from patients with chronic liver failure (CLF) and discuss the underlying molecular mechanism.
methodsBlood samples from 15 CLF patients and 15 healthy subjects were retrospectively analyzed. Primary hepatocytes were isolated using a modified two-step collagenase perfusion method. The optimal concentration of DHQ (20 μmol/L) was determined using the Cell Counting Kit-8 (CCK-8) assay. Cells were divided into a control group, a plasma group, and a DHQ intervention group. The assessed indicators included cell viability (CCK-8), apoptosis rate (flow cytometry), inflammatory factors (IL-1β, IL-6, TNF-α; ELISA), oxidative stress markers (MDA, SOD, GSH-Px), mitochondrial function (JC-1 staining, mtDNA/nDNA ratio) and related protein expression (Western blot).
resultsDHQ adjunctive therapy reduced serum circulating mitochondrial DNA levels in patients with CLF, increased serum SOD2 and Humanin expression, inhibited activation of the NLRP3-mediated pyroptotic pathway, improved remission rates of decompensated complications, and showed favorable safety and tolerability in patients with end-stage liver diseases. In vitro, hepatocyte viability was markedly decreased in the CLF group, with increased apoptosis, elevated IL-1β, IL-6, TNF-α, and MDA levels, as well as declined SOD and GSH-Px activities. DHQ reduced apoptosis, up-regulated mitochondrial functional markers (SOD2, Humanin), restored JC-1 red/green fluorescence ratios, inhibited NLR family pyrin domain-containing 3 (NLRP3) inflammasome activation, and suppressed the caspase-1/IL-1β axis.
conclusionDHQ exerts multidimensional protective effects on hepatocytes, providing a novel strategy and clinical evidence for mitochondria-targeted CLF therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.